EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)

Phase 1 Evaluation of the Bioequivalence and Drug‐Drug Interaction Potential of a Novel Fixed‐Dose Combination of Ezetimibe, Atorvastatin, and Amlodipine

Hyung Soon Lim, Jae Hoon Kim, Jang Hee Hong, Jin-Gyu Jung, Jung Sunwoo

Clinical Pharmacology in Drug Development · 2024

DOI: 10.1002/cpdd.1472 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2024. Verfasst von Hyung Soon Lim und 4 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Trials Center, Chungnam National University Hospital, Daejeon, Republic of Korea. Hauptthemen laut MEDLINE: Amlodipine, Therapeutic Equivalency, Drug Interactions, Atorvastatin. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 13 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A fixed‐dose combination (FDC) of ezetimibe, atorvastatin, and amlodipine has been developed to improve medication adherence among patients with cardiovascular diseases. In a randomized, open‐label, multiple‐dose, fixed‐sequence study involving 34 participants (Study 1), the potential drug‐drug interaction between ezetimibe/atorvastatin FDC and amlodipine was evaluated. Additionally, a randomized, open‐label, crossover study with 60 participants (Study 2) compared the pharmacokinetics (PKs) of ezetimibe/atorvastatin/amlodipine FDC to those of individual formulations. Co‐administration of the ezetimibe/atorvastatin FDC and amlodipine did not significantly alter the PKs of either drug. However, amlodipine resulted in a slight increase in systemic exposure to atorvastatin by approximately 23%. Geometric mean ratios (FDC to individual formulations) and 90% confidence intervals of area under the time‐concentration curve at steady state during dosing interval (AUC τ, ss ) and maximum concentration at steady state (C max, ss ) or amlodipine, atorvastatin, and ezetimibe were all within the bioequivalent range (0.8‐1.25), confirming bioequivalence. Moreover, the FDC of ezetimibe, atorvastatin, and amlodipine exhibited comparable tolerability to corresponding individual formulations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AmlodipineTherapeutic EquivalencyDrug InteractionsAtorvastatinCross-Over StudiesEzetimibeDrug CombinationsAnticholesteremic AgentsHumansMaleFemaleAdultMiddle AgedArea Under CurveYoung Adult

Stichwörter der Autor:innen

amlodipineatorvastatinezetimibefixed‐dose combinationpharmacokinetics

Substanzen

AmlodipineAtorvastatinEzetimibeDrug CombinationsAnticholesteremic Agents

Autor:innen und Institutionen

  • Clinical Trials Center, Chungnam National University Hospital, Daejeon, Republic of Korea.
  • Department of Medical Science, Chungnam National University College of Medicine, Daejeon, Republic of Korea.
  • Department of Pharmacology, Chungnam National University College of Medicine, Daejeon, Republic of Korea.
  • Department of Family Medicine, Chungnam National University Hospital, Daejeon, Republic of Korea.

Zitieren

APA

Lim, H. S., Kim, J. H., Hong, J. H., Jung, J. G., & Sunwoo, J. (2024). Phase 1 Evaluation of the Bioequivalence and Drug‐Drug Interaction Potential of a Novel Fixed‐Dose Combination of Ezetimibe, Atorvastatin, and Amlodipine. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1472

Vancouver

Lim HS, Kim JH, Hong JH, Jung JG, Sunwoo J. Phase 1 Evaluation of the Bioequivalence and Drug‐Drug Interaction Potential of a Novel Fixed‐Dose Combination of Ezetimibe, Atorvastatin, and Amlodipine. Clinical Pharmacology in Drug Development. 2024. doi:10.1002/cpdd.1472

BibTeX
@article{Lim2024,
  author = {Lim, Hyung Soon and Kim, Jae Hoon and Hong, Jang Hee and Jung, Jin-Gyu and Sunwoo, Jung},
  title = {Phase 1 Evaluation of the Bioequivalence and Drug‐Drug Interaction Potential of a Novel Fixed‐Dose Combination of Ezetimibe, Atorvastatin, and Amlodipine},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2024},
  doi = {10.1002/cpdd.1472}
}
Kostenlos starten →